Evotec
EvotecContent by Evotec
| 2 min read
The milestone marks meaningful progress toward developing new therapeutic options for Alport syndrome, with first-patient dosing expected in early 2026.
| 1 min read
Ongoing collaboration aims to bring new treatments for neurodegenerative conditions closer to patients.
| 3 min read
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs.
| 4 min read
Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research.
| 6 min read
Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
Page 1 of 1 - 5 Total Items
